Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
COSCIENS Biopharma Inc. (CSCIF) had Normalized Income after Taxes of $-0.20M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$3.14M |
|
$-0.20M |
|
$1.41M |
|
$1.74M |
|
$2.72M |
|
$0.42M |
|
$-0.62M |
|
$-0.20M |
|
$-0.20M |
|
$-0.20M |
|
$-0.20M |
|
$-0.20M |
|
|
Normalized Income after Taxes |
$-0.20M |
$0.42M |
|
$0.76M |
|
1.05M |
|
1.05M |
|
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$9.69M |
|
$8.75M |
|
$9.16M |
|
$18.85M |
|
$2.24M |
|
-- |
|
$1.77M |
|
$4.01M |
|
$14.84M |
|
$14.84M |
|
$14.84M |
|
1.06M |
|
| Cash Flow Statement Financials | |
$-1.58M |
|
$-0.23M |
|
$-0.14M |
|
$7.31M |
|
$5.28M |
|
$-2.03M |
|
$0.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
55.27% |
|
13.43% |
|
13.43% |
|
-- |
|
-6.43% |
|
-6.43% |
|
$-1.57M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
1.46 |
|
1.33 |
|
67.89 |
|
-1.36% |
|
-1.36% |
|
-1.07% |
|
-1.36% |
|
$13.98 |
|
$-1.50 |
|
$-1.51 |
|